StockWatch
·
Biotechnology: Pharmaceutical Preparations
Quarterly ResultAug 6, 2026, 04:24 PM

Lyell Immunopharma Clinical Trials Advance; Q2 Net Loss $44.8M

AI Summary

Lyell Immunopharma reported a net loss of $44.8 million for the second quarter of 2026, an increase from $42.7 million in the same period last year, primarily due to higher R&D expenses. The company maintains a strong cash position of $228.0 million, providing a runway into Q3 2027. Significant clinical progress was highlighted for ronde-cel, with pivotal data expected mid-2027, and for LYL273, which showed improved safety data and an amended trial design for seamless expansion.

Key Highlights

  • Reported Q2 2026 net loss of $44.8M, compared to $42.7M in Q2 2025.
  • Research and development expenses increased to $39.5M in Q2 2026.
  • Cash, cash equivalents, and marketable securities were $228.0M as of June 30, 2026.
  • Cash runway is expected to extend into Q3 2027.
  • Ronde-cel pivotal data expected mid-2027, with BLA submission in H2 2027.
  • LYL273 safety data showed Grade ≥ 2 diarrhea/colitis reduced from 55% to 10%.
  • LYL273 U.S. Phase 1 trial amended to a Phase 1/2 design for expansion.